Drug Profile

Manogepix - Amplyx Pharmaceuticals

Alternative Names: APX-001A; E1210

Latest Information Update: 07 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eisai Co Ltd
Developer Amplyx Pharmaceuticals; Eisai Co Ltd
Class Anti-infectives; Antifungals; Small molecules
Mechanism of Action Enzyme inhibitors; GWT1 protein inhibitors; Protein synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Mycoses
No development reported Coccidioidomycosis

Most Recent Events

11 Oct 2023 Pharmacodynamics data from a preclinical trial in Mycoses presented at the IDWeek 2023 (IDW-2023)
28 Jul 2022 No recent reports of development identified for preclinical development in Coccidioidomycosis in USA (PO)
09 Jun 2022 Preclinical trials in Mycoses in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com